Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.

Abstract:

OBJECTIVE:The concept of "platinum sensitivity" has been widely applied in the management of recurrent ovarian cancer. This study aimed to evaluate the applicability of this concept to recurrent endometrial cancer. PATIENTS AND METHODS:In this multicenter retrospective cohort study, the clinical data of patients with recurrent endometrial cancer, who had a history of receiving first-line platinum-based chemotherapy and who received second-line platinum-based chemotherapy at the time of recurrence between January 2005 and December 2009 were reviewed. RESULTS:A total of 262 patients from 30 centers with initial FIGO stage classifications of I (29), II (23), III (122), and IV (88) were enrolled. In total, 153 endometrioid adenocarcinomas, 34 serous adenocarcinomas, 17 clear cell adenocarcinomas, 36 carcinosarcomas, and 22 "other" tumors were documented. The response rates for patients with platinum-free intervals of <6 months, 6-11 months, 12-23 months, and ≥24 months were 25%, 38%, 61%, and 65%, respectively. The median progression-free survival after second-line platinum-based chemotherapy for patients with platinum-free intervals of <12 months and ≥12 months was 4.4 (95% confidence interval (CI)=3.7-5.8) months and 10.3 (95% CI=8.2-12.6) months, respectively (log-rank P<0.0001), and the median overall survival was 13.8 (95% CI=10.6-18.1) months and 40.9 (95% CI=25.3-54.2) months, respectively (log-rank P<0.0001). CONCLUSION:Platinum-free interval is a predictor of response and survival after second-line platinum-based chemotherapy in patients with recurrent endometrial cancer. The concept of "platinum sensitivity" could be applicable to recurrent endometrial cancer.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Nagao S,Nishio S,Michimae H,Tanabe H,Okada S,Otsuki T,Tanioka M,Fujiwara K,Suzuki M,Kigawa J

doi

10.1016/j.ygyno.2013.09.021

subject

Has Abstract

pub_date

2013-12-01 00:00:00

pages

567-73

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(13)01195-5

journal_volume

131

pub_type

杂志文章,多中心研究
  • Management of malignant, mixed mesodermal tumors of the uterus.

    abstract::Forty-two patients with malignant, mixed mesodermal tumors of the uterus were identified by retrospective chart review. Only 2 patients were premenopausal at the time of diagnosis. Six of the patients had previously received pelvic radiotherapy. Surgical/pathologic findings were inconsistent with clinical staging in 1...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(89)80041-1

    authors: Podczaski ES,Woomert CA,Stevens CW Jr,Manetta A,Larson JE,Zaino RJ,Mortel R

    更新日期:1989-02-01 00:00:00

  • Merkel cell carcinoma of the Bartholin's gland.

    abstract:BACKGROUND:There are a few cases of "small cell neuroendocrine carcinoma" of the Bartholin's gland as well as Merkel cell carcinoma of the vulva reported in the gynecologic oncology literature, most with aggressive clinical behavior. Merkel cells were originally described in the epidermis with neuroendocrine properties...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.12.064

    authors: Khoury-Collado F,Elliott KS,Lee YC,Chen PC,Abulafia O

    更新日期:2005-06-01 00:00:00

  • The effect of obesity on survival in patients with ovarian cancer.

    abstract:OBJECTIVE:Data has suggested obesity as an independent prognostic factor for lower survival in patients with epithelial ovarian cancer (EOC). We sought to determine if obesity portends a disadvantage to surgical outcomes at the time of initial surgery affecting survival. METHODS:A retrospective chart review of patient...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.10.016

    authors: Matthews KS,Straughn JM Jr,Kemper MK,Hoskins KE,Wang W,Rocconi RP

    更新日期:2009-02-01 00:00:00

  • Control of cyclin D1 expression by antisense oligonucleotides in three ovarian cancer cell lines.

    abstract::Cyclin D1 is a critical gene controlling the G1 phase progression through the cell cycle. Alterations of cyclin D1 have been demonstrated in a variety of cancer types. We recently reported that increased cyclin D1 expression is associated with malignancy also in ovarian tumors. Three human ovarian cancer cell lines (S...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5062

    authors: Cagnoli M,Barbieri F,Bruzzo C,Alama A

    更新日期:1998-09-01 00:00:00

  • Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.

    abstract:OBJECTIVE:In vitro data and pilot data suggest that green tea catechins may possess chemopreventive activity for cervical cancer and precursor lesions. We conducted a randomized, double-blind, placebo-controlled trial of Polyphenon E (decaffeinated and enriched green tea catechin extract) in women with persistent human...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ygyno.2013.12.034

    authors: Garcia FA,Cornelison T,Nuño T,Greenspan DL,Byron JW,Hsu CH,Alberts DS,Chow HH

    更新日期:2014-02-01 00:00:00

  • Accuracy of diffusion-weighted echo-planar MR imaging and ADC mapping in the evaluation of residual cervical carcinoma after radiation therapy.

    abstract:OBJECTIVES:The impact of diffusion-weighted imaging (DWI) and apparent diffusion coefficients (ADCs) of MR imaging on the evaluation of residual Uterine Cervical Carcinoma after Radiation Therapy, in addition to conventional MR images. METHODS:Fourty-nine women presenting with a uterine cervical cancer were examined w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.06.009

    authors: Levy A,Caramella C,Chargari C,Medjhoul A,Rey A,Zareski E,Boulet B,Bidault F,Dromain C,Balleyguier C

    更新日期:2011-10-01 00:00:00

  • Metastatic cervical carcinoma to the breast.

    abstract::Metastatic disease to the breast is often an unexpected diagnosis in a female who presents with a breast mass. The most important factor suggesting the appropriate diagnosis is a history of cancer. Correlation of mammographic and ultrasonographic findings may also raise the possibility of a metastatic mass. A well-def...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90288-t

    authors: Younathan CM,Steinbach BG,DeBose CD

    更新日期:1992-05-01 00:00:00

  • Sacral metastasis in a patient with endometrial cancer: case report and review of the literature.

    abstract:BACKGROUND:Bone involvement in endometrial cancer has been described in less than 15% of the patients with metastatic disease. The medical literature reports 29 cases, although none involving the sacrum. CASE:We present a case of a 62-year-old woman who underwent surgery for endometrial adenocarcinoma in December 2002...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.04.005

    authors: Albareda J,Herrera M,Lopez Salva A,Garcia Donas J,Gonzalez R

    更新日期:2008-12-01 00:00:00

  • Assessment of inhibin and p53 in granulosa cell tumors of the ovary.

    abstract:OBJECTIVE:The goal of this work was to determine the cellular content of inhibin and p53 in granulosa cell tumors (GCTs). METHODS:Clinical records of 47 patients (mean age, 54 years; range, 20-85 years) presenting with GCT surgically managed at our institution were abstracted. International Federation of Gynecology st...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5774

    authors: Gebhart JB,Roche PC,Keeney GL,Lesnick TG,Podratz KC

    更新日期:2000-05-01 00:00:00

  • Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.

    abstract:OBJECTIVE:The aim of this study was to study the combination of intraperitoneal alpha-interferon and cisplatin administered second-line in an alternating sequence in small volume residual epithelial ovarian cancer after second-look surgery and the activity of this combination based on prior response to first-line plati...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.1999.5455

    authors: Berek JS,Markman M,Blessing JA,Kucera PR,Nelson BE,Anderson B,Hanjani P

    更新日期:1999-07-01 00:00:00

  • Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.

    abstract:OBJECTIVE:To assess the abilities of cisplatin, paclitaxel, and flexible heteroarotinoid (Flex-Het) compound (SHetA2) to sensitize ovarian cancer cells to induction of the extrinsic apoptosis pathway by death receptor ligands, tumor necrosis factor alpha (TNFalpha), and TNF-related apoptosis-inducing ligand (TRAIL). S...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.09.007

    authors: Moxley KM,Chengedza S,Benbrook DM

    更新日期:2009-12-01 00:00:00

  • Gastrointestinal stromal tumor presenting as a pelvic mass.

    abstract::Gastrointestinal stromal tumors (GISTs) are c-kit-positive tumors that may arise anywhere in the tubular gastrointestinal tract. Around 5% of the cases arise elsewhere in the abdominal cavity. Tumors originating in the omentum and mesentery have been reported.A 31-year-old woman presented with pelvic pain, a palpable ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2003.08.025

    authors: Zighelboim I,Henao G,Kunda A,Gutierrez C,Edwards C

    更新日期:2003-12-01 00:00:00

  • The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum.

    abstract::cis-Platinum is a chemotherapeutic agent with benefits often limited by the severe gastrointestinal reactions it produces in nearly all patients. Persistent anorexia, nausea, and vomiting may continue for days after therapy and are poorly controlled by conventional antiemetics. Patients at times refuse continuation of...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(85)90268-9

    authors: Benrubi GI,Norvell M,Nuss RC,Robinson H

    更新日期:1985-07-01 00:00:00

  • Endocervical curettage: does it contribute to the management of patients with abnormal cervical cytology?

    abstract::Routine endocervical curettage has been advocated in the colposcopic evaluation of patients with abnormal cervical cytology. To assess the usefulness of this procedure, we reviewed the records of 518 patients referred to the Colposcopy Clinic with abnormal Pap smears. Data was reviewed retrospectively in 411 patients ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90100-9

    authors: Oyer R,Hanjani P

    更新日期:1986-10-01 00:00:00

  • Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.

    abstract:PURPOSE:The MDS1 and EVI1 complex locus (MECOM) at 3q26 gives rise to several alternatively spliced transcripts implicated in leukemic oncogenesis. Overexpression of EVI1 in ovarian cancer has led to a proposed oncogenic role. Our objective was to evaluate the therapeutic potential of EVI1 and EVI1s (also known as Delt...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.04.007

    authors: Jazaeri AA,Ferriss JS,Bryant JL,Dalton MS,Dutta A

    更新日期:2010-08-01 00:00:00

  • Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.

    abstract:OBJECTIVES:The aim of this study was to evaluate the effect of number of chemotherapy cycles and other clinical and pathologic factors on progression-free (PFS) and overall survival (OS) in patients with newly diagnosed cervical cancer. METHODS:We identified 118 patients with locally advanced cervical cancer (stages I...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.09.045

    authors: Nugent EK,Case AS,Hoff JT,Zighelboim I,DeWitt LL,Trinkhaus K,Mutch DG,Thaker PH,Massad LS,Rader JS

    更新日期:2010-03-01 00:00:00

  • Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

    abstract:BACKGROUND:To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). METHODS:A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2015.06.041

    authors: Fuh KC,Secord AA,Bevis KS,Huh W,ElNaggar A,Blansit K,Previs R,Tillmanns T,Kapp DS,Chan JK

    更新日期:2015-12-01 00:00:00

  • A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.

    abstract:OBJECTIVES:The objectives of this multicenter phase II study were to evaluate the effects of gemcitabine-paclitaxel-cisplatin combination chemotherapy on response rate, survival, and toxicity in patients with advanced epithelial ovarian cancer (AEOC). METHODS:Chemonaive AEOC patients with bidimensionally measurable di...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.ygyno.2005.03.032

    authors: Gupta SK,John S,Naik R,Arora R,Selvamani B,Fuloria J,Ganesh N,Awasthy BS

    更新日期:2005-07-01 00:00:00

  • Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.

    abstract:OBJECTIVE:This study was performed to define the subgroups of patients who benefit from postoperative adjuvant chemotherapy in stage I and II endometrial carcinoma. METHODS:A retrospective review of 170 International Federation of Gynecology and Obstetrics (FIGO) stage I and II endometrial carcinoma patients treated b...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.05.040

    authors: Aoki Y,Watanabe M,Amikura T,Obata H,Sekine M,Yahata T,Fujita K,Tanaka K

    更新日期:2004-08-01 00:00:00

  • Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.

    abstract:OBJECTIVE:Chimeric antigen receptor (CAR)-T cell strategies ideally target a surface antigen that is exclusively and uniformly expressed by tumors; however, no such antigen is known for high-grade serous ovarian carcinoma (HGSC). A potential solution involves combinatorial antigen targeting with AND or OR logic-gating....

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.12.005

    authors: Banville AC,Wouters MCA,Oberg AL,Goergen KM,Maurer MJ,Milne K,Ashkani J,Field E,Ghesquiere C,Jones SJM,Block MS,Nelson BH

    更新日期:2021-02-01 00:00:00

  • Clinicopathologic features of villoglandular papillary adenocarcinoma of the uterine cervix.

    abstract:OBJECTIVES:The objectives of this study are to analyze the clinicopathologic features of villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix and to discuss the management thereof. We examined 13 patients with VGPA. METHODS:Clinical profiles, including patient age, clinical stage, surgical procedure, a...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2003.10.020

    authors: Utsugi K,Shimizu Y,Akiyama F,Umezawa S,Hasumi K

    更新日期:2004-01-01 00:00:00

  • Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer.

    abstract:OBJECTIVE:Ovarian cancer is most frequently diagnosed at a late stage with a poor prognosis. No markers for early diagnosis have been established. Aberrantly methylated DNA appears as a promising molecular cancer marker. The aim of this study was to analyze the methylation status of the proapoptotic cancer related gene...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.11.018

    authors: Häfner N,Diebolder H,Jansen L,Hoppe I,Dürst M,Runnebaum IB

    更新日期:2011-04-01 00:00:00

  • Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature.

    abstract:BACKGROUND:Gestational choriocarcinoma is a malignant tumor that frequently metastasizes to the highly vascularized organs such as the lung, brain, and liver via hematogenous spread. However, this tumor rarely metastasizes to the eye and only a few cases of metastasis to the choroid have been reported. CASE:A 17-year-...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.2001.6415

    authors: Ino K,Mitsui T,Nomura S,Kikkawa F,Mizutani S

    更新日期:2001-12-01 00:00:00

  • Impact of obesity on surgical and oncologic outcomes in ovarian cancer.

    abstract:OBJECTIVES:The aim of this study is to determine the impact of obesity on surgical and oncologic outcomes after primary debulking surgery (PDS) in advanced epithelial ovarian cancer (EOC). METHODS:Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/2/2003 and 12/30/2011 were included. Patient...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.07.103

    authors: Kumar A,Bakkum-Gamez JN,Weaver AL,McGree ME,Cliby WA

    更新日期:2014-10-01 00:00:00

  • Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis.

    abstract:OBJECTIVE:Currently available epidemiologic evidences concerning the chemopreventive effect of aspirin on ovarian cancer are inconsistent. Therefore, we aimed to further explore the association by synthesizing evidence from population-based studies. METHODS:We searched PubMed, EMBASE, Web of Science, and Scopus using ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ygyno.2016.04.543

    authors: Zhang D,Bai B,Xi Y,Wang T,Zhao Y

    更新日期:2016-08-01 00:00:00

  • The Patient Protection and Affordable Care Act: impact on the care of gynecologic oncology patients in the absence of Medicaid expansion in central Virginia.

    abstract:OBJECTIVE:Many gynecologic oncology (GO) patients in Virginia are low income and their care is supplemented by Disproportionate Share Hospital (DSH) funds. Our objective is to estimate how many new GO patients may lose access to care if the state forgoes Medicaid expansion. METHODS:New patients referred to the GO serv...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.04.468

    authors: Courtney-Brooks M,Pelkofski EB,Engelhard CL,Duska LR

    更新日期:2013-08-01 00:00:00

  • Bone metastasis from cervix cancer.

    abstract::Among 713 patients followed after treatment for cancer of the uterine cervix, 48 (6.6%) had a metastasis to the bone. The rates of metastasis in each of the four clinical stages were 11/273 (4.0%) in stage I, 16/243 (6.6%) in stage II, 13/162 (8.0%) in stage III, and 8/35 (22.9%) in stage IV, respectively. The most fr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90853-6

    authors: Matsuyama T,Tsukamoto N,Imachi M,Nakano H

    更新日期:1989-01-01 00:00:00

  • Characterization of peripheral blood and ovarian cancer-infiltrating lymphocytes: effect of HIV infection on phenotypic expression and proliferative response.

    abstract::A study that focused on the identification of the phenotype and proliferative responses of peripheral blood and ovarian cancer-infiltrating lymphocytes in a patient with stage III ovarian cancer who had human immunodeficiency virus infection is presented. Monoclonal antibodies and flow cytometry were used to determine...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1994.1126

    authors: Guidozzi F,Reddy S,Wadee A

    更新日期:1994-05-01 00:00:00

  • Bokhman Redux: Endometrial cancer "types" in the 21st century.

    abstract::In 1983 Jan V. Bokhman, M.D. published a landmark paper entitled "Two Pathogenetic Types of Endometrial Carcinoma" in which an enduring dualistic view of endometrial cancer was first proposed. "Type I" cancers are thought to represent estrogen driven mostly low grade endometrioid tumors strongly associated with obesit...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2016.12.010

    authors: Suarez AA,Felix AS,Cohn DE

    更新日期:2017-02-01 00:00:00

  • A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

    abstract:OBJECTIVES:A phase II trial was conducted to evaluate the anti-tumor activity and adverse effects of thalidomide in persistent or recurrent endometrial cancer refractory to cytotoxic chemotherapy and to correlate angiogenesis biomarker expression with clinical outcome. METHODS:Consenting patients were treated until pr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2007.01.019

    authors: McMeekin DS,Sill MW,Benbrook D,Darcy KM,Stearns-Kurosawa DJ,Eaton L,Yamada SD,Gynecologic Oncology Group.

    更新日期:2007-05-01 00:00:00